Mount Capital’s Moderna MRNA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$44.4M Sell
230,416
-227,484
-50% -$24.5M 13.94% 2
2026
Q2
$32.1M Buy
457,900
+62,700
+16% +$3.24M 12.1% 3
2026
Q1
$20.1M Buy
+395,200
New +$18.4M 8.09% 5

Other funds holding MRNA

Mount Capital's MRNA Position: Q3 2026 in Review

Mount Capital reduced its Moderna (MRNA) stake by 50% in Q3 2026, selling an estimated $24.5M and leaving 230,416 shares worth $44.4M. The position accounts for 13.94% of the portfolio, ranked #2.

Mount Capital first reported a position in MRNA in Q1 2026 and has held it in 3 quarters since. 1,053 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Mount Capital held 230,416 shares of Moderna worth $44.4M as of Q3 2026.
  • Mount Capital sold 227,484 Moderna shares in Q3 2026, an estimated $24.5M.
  • Moderna made up 13.94% of Mount Capital's portfolio in Q3 2026, its #2 holding.
  • Mount Capital first reported a position in Moderna in Q1 2026 and has held it in 3 quarters since.
  • 1,053 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Mount Capital's 13F filing for Q3 2026, filed 13 Nov 2026.